Per Soelberg Sorensen

Summary

Affiliation: Copenhagen University Hospital
Country: Denmark

Publications

  1. doi request reprint NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial
    Per Soelberg Sorensen
    Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Lancet Neurol 8:519-29. 2009
  2. pmc Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
    Jeppe Romme Christensen
    Department of Neurology, Danish Multiple Sclerosis Center, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, Copenhagen, 2100, Denmark
    J Neuroinflammation 9:215. 2012
  3. doi request reprint Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
    Per Soelberg Sørensen
    Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet and Copenhagen University, Denmark
    Mult Scler 18:143-52. 2012
  4. ncbi request reprint The relationship between MRI and PET changes and cognitive disturbances in MS
    Per Soelberg Sørensen
    Department of Neurology 2082, Danish MS Research Center, Copenhagen University Hospital, Rigshospitalet, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    J Neurol Sci 245:99-102. 2006
  5. ncbi request reprint Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis
    P S Sorensen
    MS Research Unit, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Eur J Neurol 9:557-63. 2002
  6. ncbi request reprint Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS
    P Soelberg Sorensen
    Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Neurology 67:1681-3. 2006
  7. ncbi request reprint The gap between effect of drugs and effectiveness of treatments
    Per Soelberg Sorensen
    Copenhagen Multiple Sclerosis Research Center, Department of Neurology 2082, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    J Neurol Sci 259:128-32. 2007
  8. ncbi request reprint Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
    P S Sorensen
    Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Mult Scler 13:616-21. 2007
  9. ncbi request reprint Intravenous polyclonal human immunoglobulins in multiple sclerosis
    Per Soelberg Sorensen
    Danish MS Research Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Neurodegener Dis 5:8-15. 2008
  10. ncbi request reprint [Biological treatment of multiple sclerosis]
    Per Soelberg Sørensen
    Rigshospitalet, Dansk Multipel Sclerose Center, Neurologisk Afdeling 2082, København Ø
    Ugeskr Laeger 170:2156-9. 2008

Detail Information

Publications36

  1. doi request reprint NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial
    Per Soelberg Sorensen
    Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Lancet Neurol 8:519-29. 2009
    ..Our aim was to assess the efficacy of oral methylprednisolone as an add-on therapy to subcutaneous interferon beta-1a to reduce the yearly relapse rate in patients with relapsing-remitting multiple sclerosis...
  2. pmc Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
    Jeppe Romme Christensen
    Department of Neurology, Danish Multiple Sclerosis Center, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, Copenhagen, 2100, Denmark
    J Neuroinflammation 9:215. 2012
    ..Knowledge about the relation between blood and cerebrospinal fluid (CSF) cell expression of cytokines and the cellular source of CSF cytokines is even more scarce...
  3. doi request reprint Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
    Per Soelberg Sørensen
    Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet and Copenhagen University, Denmark
    Mult Scler 18:143-52. 2012
    ..Continued research and data collection will further develop our understanding of PML and the mechanisms by which these risk factors contribute to its development...
  4. ncbi request reprint The relationship between MRI and PET changes and cognitive disturbances in MS
    Per Soelberg Sørensen
    Department of Neurology 2082, Danish MS Research Center, Copenhagen University Hospital, Rigshospitalet, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    J Neurol Sci 245:99-102. 2006
    ..Measurements of global NAA using multi-slice EPSI is a new promising method for measurement of the global neuron capacity and can be repeated with only little discomfort and without any risk for the patient...
  5. ncbi request reprint Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis
    P S Sorensen
    MS Research Unit, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Eur J Neurol 9:557-63. 2002
    ..IVIG could be considered in patients who do not tolerate or are unwilling to take the approved injectable medications, but additional studies are needed to establish the role of IVIG in the management of multiple sclerosis...
  6. ncbi request reprint Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS
    P Soelberg Sorensen
    Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Neurology 67:1681-3. 2006
    ..High-level NAB patients had more MRI activity than NAB-negative patients (p = 0.031). Patients with a full response had less MRI activity than patients without biologic response (p = 0.032)...
  7. ncbi request reprint The gap between effect of drugs and effectiveness of treatments
    Per Soelberg Sorensen
    Copenhagen Multiple Sclerosis Research Center, Department of Neurology 2082, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    J Neurol Sci 259:128-32. 2007
    ..However, this may not be obtained from a single drug but may require combinations of drugs with different actions on the disease processes...
  8. ncbi request reprint Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
    P S Sorensen
    Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Mult Scler 13:616-21. 2007
    ..With affinity maturation, NAbs effectively prevent IFN-beta binding to its receptors also in vivo and, hence, abolish the treatment effect...
  9. ncbi request reprint Intravenous polyclonal human immunoglobulins in multiple sclerosis
    Per Soelberg Sorensen
    Danish MS Research Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Neurodegener Dis 5:8-15. 2008
    ....
  10. ncbi request reprint [Biological treatment of multiple sclerosis]
    Per Soelberg Sørensen
    Rigshospitalet, Dansk Multipel Sclerose Center, Neurologisk Afdeling 2082, København Ø
    Ugeskr Laeger 170:2156-9. 2008
    ..However, the monoclonal antibodies generally have a less favourable safety profile and are more expensive than the currently used first-line therapies, IFNb and glatiramer acetate...
  11. doi request reprint Oral fumarate for relapsing-remitting multiple sclerosis
    Per Soelberg Sorensen
    Danish Multiple Sclerosis Research Center, Department of Neurology, Rigshospitalet, DK 2100, Copenhagen, Denmark
    Lancet 372:1447-8. 2008
  12. pmc Neutralizing antibodies against interferon-Beta
    Per Soelberg Sorensen
    Danish Multiple Sclerosis Research Center Department of Neurology 2082, Copenhagen University Hospital Rigshospitalet, DK 2100 Copenhagen, Denmark
    Ther Adv Neurol Disord 1:62-78. 2008
    ..As low and medium titers are ambiguous treatment decisions in patients with low NAb titres should be guided by determination of in vivo mRNA MxA induction and clinical disease activity...
  13. doi request reprint Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial
    Per Soelberg Sorensen
    Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Lancet Neurol 10:691-701. 2011
    ..Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective. We aimed to establish whether add-on of simvastatin, a statin with anti-inflammatory properties, improves this efficacy...
  14. ncbi request reprint Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis
    P S Sørensen
    Danish Multiple Sclerosis Research Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Eur J Neurol 12:817-27. 2005
    ..In patient with NABs, measurements should be repeated, and therapy with IFN-beta should be discontinued in patients with high titres of NABs sustained at repeated measurements with 3- to 6-month intervals (Level A recommendation)...
  15. ncbi request reprint [Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis]
    Soelberg Sørensen
    Sclerose Forskningsenheden, Københavns MS Center, Neurologisk Afdeling 2082, H S Rigshospitalet
    Ugeskr Laeger 166:3606-9. 2004
  16. ncbi request reprint Early-stage multiple sclerosis : what are the treatment options?
    Per Soelberg Sorensen
    Copenhagen MS Centre, The Neuroscience Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Drugs 64:2021-9. 2004
    ..However, further prolonged studies are needed to investigate the long-term benefit of early-stage treatment in MS...
  17. ncbi request reprint Antibodies to IFN-beta: the Danish National IFN-beta Project
    Per Soelberg Sorensen
    Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Neurology 61:S27-8. 2003
  18. ncbi request reprint IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS
    P Soelberg Sorensen
    MS Research Unit, Department of Neurology 2082, Copenhagen University Hospital, Rigshospitalet, DK 2100 Copenhagen, Denmark
    Neurology 63:2028-33. 2004
    ..To investigate if IV immunoglobulins (IVIg) in combination with methylprednisolone make recovery from a relapse faster and more complete than methylprednisolone alone. Design/..
  19. ncbi request reprint Appearance and disappearance of neutralizing antibodies during interferon-beta therapy
    P Soelberg Sorensen
    Copenhagen MS Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, DK 2100 Copenhagen, Denmark
    Neurology 65:33-9. 2005
    ....
  20. ncbi request reprint Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
    Per Soelberg Sorensen
    Department of Neurology, Institute for Inflammation Research, Rigshospitalet, Copenhagen, Denmark
    Lancet 362:1184-91. 2003
    ..We aimed to assess the clinical effect of neutralising antibodies...
  21. ncbi request reprint Multiple sclerosis: pathophysiology revisited
    Per Soelberg Sorensen
    Copenhagen Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Lancet Neurol 4:9-10. 2005
  22. ncbi request reprint IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions
    Signe Humle Jorgensen
    Danish MS Research Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet sect 6311, 2100 Copenhagen, Denmar
    Exp Brain Res 178:462-9. 2007
    ..In conclusion, the results indicate that significant extravasation of IVIG to the CNS only occurs when blood-brain barrier function is compromised during EAE...
  23. ncbi request reprint Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis
    Bodil Petersen
    Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Mult Scler 12:247-52. 2006
    ..The main objective was to follow serum levels of neutralizing antibodies (NABs) against interferon-beta (IFNbeta) after discontinuation of IFNbeta therapy...
  24. ncbi request reprint Multi-slice echo-planar spectroscopic MR imaging provides both global and local metabolite measures in multiple sclerosis
    Henrik Kahr Mathiesen
    Danish Research Centre for Magnetic Resonance, Copenhagen University Hospital, Kettegaard Alle 30, DK 2650 Hvidovre, Denmark
    Magn Reson Med 53:750-9. 2005
    ..The reproducibility of the technique makes it a promising tool for future longitudinal spectroscopic studies of MS...
  25. ncbi request reprint The role of intravenous immunoglobulin in the treatment of multiple sclerosis
    Per Soelberg Sorensen
    MS Research Unit, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, DK 2100 Copenhagen, Denmark
    J Neurol Sci 206:123-30. 2003
    ....
  26. ncbi request reprint Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically
    Signe Humle Jorgensen
    Danish MS Centre, Copenhagen University Hospital, Rigshospitalet sect 9202, DK 2100 Copenhagen, Denmark
    Neurol Res 27:591-7. 2005
    ..EAE was induced in susceptible Dark Agouti rats by active immunization with a spinal cord homogenate, and infusions of 1 g/kg IVIG were given prophylactically or therapeutically...
  27. doi request reprint Why does the north-south gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere?
    Nils Koch-Henriksen
    Department of Neurology, Aarhus University Hospital in Aalborg, Denmark
    J Neurol Sci 311:58-63. 2011
    ..In addition, we observed in most regions a profound increase in female incidence of MS. The last observation should prompt epidemiological studies focusing on change in female life style...
  28. ncbi request reprint Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis
    Signe Humle Jorgensen
    Copenhagen MS Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, DK 2100 Copenhagen, Denmark
    J Neurol Sci 233:61-5. 2005
    ..IVIG is, therefore, presently regarded as a second-line therapy of MS...
  29. ncbi request reprint Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis
    Rachel Farrell
    J Int Med Res 36:204-8; author reply 208-10. 2008
  30. ncbi request reprint Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis
    Timothy K Vartanian
    Multiple Sclerosis Division, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    Neurology 63:S42-9. 2004
    ..Long-term prospective studies are needed to further define the clinical effects of NAbs on patients receiving disease-modifying therapies for MS...
  31. ncbi request reprint Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
    Per Soelberg Sorensen
    Neurology 69:1552; author reply 1553. 2007
  32. ncbi request reprint Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report
    Hans P Hartung
    Dept of Neurology, Heinrich Heine University, Moorenstrasse 5, 40225, Dusseldorf, Germany
    J Neurol 254:827-37. 2007
    ....
  33. ncbi request reprint Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis
    Henrik Kahr Mathiesen
    Danish Research Centre for Magnetic Resonance, Copenhagen University Hospital Hvidovre, Kettegaard Alle 30, DK 2650 Hvidovre, Denmark
    Arch Neurol 63:533-6. 2006
    ..Whole-brain N-acetyl aspartate (NAA), a measure of neuronal function, can be assessed by multislice echo-planar spectroscopic imaging...
  34. ncbi request reprint Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations
    Elliot M Frohman
    Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Arch Neurol 62:1519-30. 2005
    ....
  35. ncbi request reprint Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients
    Hanne F Harbo
    Institute of Immunology, Rikshospitalet University Hospital, 0027 Oslo, Norway
    J Neuroimmunol 143:101-6. 2003
    ..Usable data were achieved from the same 3331 markers in both screens. Nine markers from eight genomic regions (1p33, 3q13, 6p21, 6q14, 7p22, 9p21, 9q21 and Xq22) were identified as potentially associated with MS in both screens...
  36. ncbi request reprint Remyelination is extensive in a subset of multiple sclerosis patients
    Peter Patrikios
    Center for Brain Research, Medical University of Vienna, Vienna, Austria
    Brain 129:3165-72. 2006
    ..These results suggest that the variable and patient-dependent extent of remyelination must be considered in the design of future clinical trials aimed at promoting CNS repair...